NCT02953704 is a clinical trial in MPN (Myeloproliferative Neoplasms), sponsored by Incyte Corporation.

Who is sponsoring NCT02953704?

NCT02953704 is sponsored by Incyte Corporation.

What condition does NCT02953704 study?

NCT02953704 studies MPN (Myeloproliferative Neoplasms).

Is NCT02953704 still recruiting?

NCT02953704 is currently completed. Last updated 13 May 2022.

Last reviewed 2022-05-13 · How we verify

NCT02953704

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

Completed Last updated 13 May 2022

What this trial tests

trial in MPN (Myeloproliferative Neoplasms) in 1,469 participants. Completed in 29 March 2022.

Timeline

31 December 2016

Primary endpoint
29 March 2022

29 March 2022

Quick facts

Lead sponsor	Incyte Corporation
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,469
Start date	31 December 2016
Primary completion	29 March 2022
Estimated completion	29 March 2022
Sites	116 locations across Puerto Rico, United States

Conditions studied

MPN (Myeloproliferative Neoplasms) — all drugs for MPN (Myeloproliferative Neoplasms) →

Sponsor

Incyte Corporation — full company profile →

Who can join

18 and older, any sex, with MPN (Myeloproliferative Neoplasms). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this prospective, longitudinal, noninterventional study is to describe clinical characteristics, evolution of disease burden, and treatment patterns in patients with select subcategories of essential thrombocythemia (ET) or myelofibrosis (MF).

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Essential Thrombocythemia Enrolled in the MOST Study.
Yacoub A, Lyons R, Verstovsek S, Shao R, et al · · 2021 · cited 4× · PMID 33839074 · DOI 10.1016/j.clml.2021.02.011
Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study.
Gerds AT, Lyons RM, Colucci P, Kalafut P, et al · · 2022 · cited 3× · PMID 35256316 · DOI 10.1016/j.clml.2022.02.001
Patient-reported outcomes of patients with myelofibrosis or essential thrombocythemia enrolled in the MOST study.
Ritchie E, Al-Janadi A, Kessler C, Scherber R, et al · · 2022 · cited 2× · PMID 36205505 · DOI 10.1080/10428194.2022.2113531
Treatment comparison of hydroxyurea versus ruxolitinib in essential thrombocythaemia: A matched-cohort analysis.
Grunwald MR, Ritchie EK, Rumi E, Assad A, et al · · 2024 · PMID 39157625 · DOI 10.1002/jha2.954
EHA2024 Hybrid Congress
· 2024
P1046: TREATMENT COMPARISON OF HYDROXYUREA VS RUXOLITINIB IN ESSENTIAL THROMBOCYTHEMIA (ET): A MATCHED COHORT ANALYSIS
Grunwald M, Ritchie E, Rumi E, Assad A, et al · · 2023
P1045: DISEASE PROGRESSION AND LEUKEMIC TRANSFORMATION IN PATIENTS WITH LOWER-RISK MYELOFIBROSIS: AN ANALYSIS FROM MOST
Komrokji R, Grunwald M, Braunstein E, Hamer-Maansson J, et al · · 2023

Verify or expand the search:

Other recruiting trials for MPN (Myeloproliferative Neoplasms)

Currently open trials in the same condition.

NCT07362225 — MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel · recruiting

Other Incyte Corporation trials

Trials by the same sponsor.

NCT07124078 — A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Di · Phase 2 · recruiting
NCT07441694 — Study of INCA036978 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
NCT07284849 — A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02953704 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Incyte Corporation
Last refreshed: 13 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02953704.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing